Esta tradução está a ser preparada. Entretanto, mostramos temporariamente a versão original em inglês.
Negócios · 27/01/19991 min de leitura
Agency Information Collection Activities; Announcement of OMB Approval; Guidance for Industry: Current Good Manufacturing Practice for Blood and Blood Components: (1) Quarantine and Disposition of Units From Prior Collections From Donors with Repeatedly Reactive Screening Test for Antibody to Hepatitis C Virus (Anti-HCV); (2) Supplemental Testing, and the Notification of Consignees and Blood Recipients of Donor Test Results for Anti-HCV
Tradução automática local · Idioma original da fonte
Resumo
The Food and Drug Administration (FDA) is announcing that a collection of information entitled ``Guidance for Industry: Current Good Manufacturing Practice for Blood and Blood Components: (1) Quarantine and Disposition of Units From Prior Collections From Donors with Repeatedly Reactive Screening Test for Antibody to Hepatitis C Virus (Anti-HCV); (2) Supplemental Testing, and the Notification of Consignees and Blood Recipients of Donor Test Results for Anti-HCV'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Idioma original da fonte: Federal Register — Food and Drug AdministrationAbrir o comunicado original →